February 19, 2020 07:15 AM ESTUpdated 12:38 PM
Pharma
FDA+

As blue­bird makes com­mer­cial progress in Eu­rope, US ap­pli­ca­tion for Zyn­te­glo suf­fers de­lay

Natalie Grover

Reporter

Af­ter shock­ing Wall Street with a $1.8 mil­lion price tag for its gene ther­a­py Zyn­te­glo in Eu­rope — blue­bird bio on Tues­day re­vealed that it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

A service from the Financial Times